- Home
- JANX vs PTY Comparison
JANX vs PTY Comparison
Compare JANX & PTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- PTY
- Stock Information
- Founded
- JANX 2017
- PTY 2002
- Country
- JANX United States
- PTY United States
- Employees
- JANX N/A
- PTY N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- PTY Investment Managers
- Sector
- JANX Health Care
- PTY Finance
- Exchange
- JANX Nasdaq
- PTY Nasdaq
- Market Cap
- JANX 2.2B
- PTY 2.2B
- IPO Year
- JANX 2021
- PTY N/A
- Fundamental
- Price
- JANX $26.81
- PTY $14.49
- Analyst Decision
- JANX Strong Buy
- PTY
- Analyst Count
- JANX 8
- PTY 0
- Target Price
- JANX $91.25
- PTY N/A
- AVG Volume (30 Days)
- JANX 784.7K
- PTY 550.4K
- Earning Date
- JANX 05-06-2025
- PTY 01-01-0001
- Dividend Yield
- JANX N/A
- PTY 9.65%
- EPS Growth
- JANX N/A
- PTY N/A
- EPS
- JANX N/A
- PTY N/A
- Revenue
- JANX $10,588,000.00
- PTY N/A
- Revenue This Year
- JANX N/A
- PTY N/A
- Revenue Next Year
- JANX $289.47
- PTY N/A
- P/E Ratio
- JANX N/A
- PTY N/A
- Revenue Growth
- JANX 30.99
- PTY N/A
- 52 Week Low
- JANX $26.39
- PTY $11.92
- 52 Week High
- JANX $71.71
- PTY $14.88
- Technical
- Relative Strength Index (RSI)
- JANX 29.87
- PTY 51.33
- Support Level
- JANX $29.77
- PTY $14.30
- Resistance Level
- JANX $32.00
- PTY $14.52
- Average True Range (ATR)
- JANX 1.44
- PTY 0.07
- MACD
- JANX -0.00
- PTY 0.02
- Stochastic Oscillator
- JANX 7.01
- PTY 90.62
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.